WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/058797    International Application No.:    PCT/US2008/081493
Publication Date: 07.05.2009 International Filing Date: 29.10.2008
Chapter 2 Demand Filed:    01.09.2009    
C07K 16/18 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, IN 46285 (US) (For All Designated States Except US).
CAI, Yuping, Anthony [CN/US]; (US) (For US Only).
GATELY, Dennis, Patrick [US/US]; (US) (For US Only).
HE, Luhong [US/US]; (US) (For US Only).
LEUNG, Donmienne, Doen [AU/US]; (US) (For US Only).
LUAN, Peng [CN/US]; (US) (For US Only).
SWANSON, Barbara, Anne [US/US]; (US) (For US Only).
TANG, Ying [CN/US]; (US) (For US Only).
WITCHER, Derrick, Ryan [US/US]; (US) (For US Only)
Inventors: CAI, Yuping, Anthony; (US).
GATELY, Dennis, Patrick; (US).
HE, Luhong; (US).
LEUNG, Donmienne, Doen; (US).
LUAN, Peng; (US).
SWANSON, Barbara, Anne; (US).
TANG, Ying; (US).
WITCHER, Derrick, Ryan; (US)
Agent: SHARP, Robert, L.; Eli Lilly and Company Patent Division P. O. Box 6288 Indianapolis, IN 46206-6288 (US)
Priority Data:
60/984,910 02.11.2007 US
Abstract: front page image
(EN)Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.
(FR)L'invention porte sur des anticorps monoclonaux se fixant sélectivement sur l'hepcidine-25 humaine et se caractérisant par leur forte affinité pour l'hepcidine-25 humaine et leurs fortes propriétés de neutralisation de l'hepcidine mûre. Lesdits anticorps sont thérapeutiquement utiles pour accroître les niveaux de fer sérique, la numération des réticulocytes, la numération des érythrocytes, l'hémoglobine, et/ou les hématocrites chez l'homme et pour le traitement et le diagnostic de troubles médiés par l'hepcidine mûre, tels que l'anémie chez l'homme.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)